Biological Identity of Nanoparticles In Vivo : Clinical Implications of the Protein Corona
Abstract
Despite the advances in biomedical applications of nanoparticle (NP) and numerous publications, few NPs have made it to clinical trials and even fewer have reached clinical practice. This wide gap between bench discoveries and clinical applications is mainly because of our limited understanding of the biological identity of NPs. In physiological environments, NPs are coated by a 'protein corona' (PC), critically affecting physiological and therapeutic responses. To date, nearly all studies attempting to characterize the PC have been conducted in vitro. Here, we review recent advances in our understanding of the in vivo PC. We also discuss recent developments of quantitative models to predict biological interactions and how they offer new opportunities for the clinical translation of NPs.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Protein corona presents a major obstacle to bench-to-bedside translation of targeted drug delivery systems, severely affecting targeting yields and directing unfavorable biodistribution.
“Protein corona presents a major obstacle to bench-to-bedside translation of targeted drug delivery systems, severely affecting targeting yields and directing unfavorable biodistribution.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [8]
Plasma protein absorption on liposomal surface is inevitable even in the presence of PEG.
“Unfortunately, plasma protein absorption on liposomal surface is inevitable even in the presence of PEG8,48,49.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [8]
Cites
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220 · see citing works
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506 · see citing works
Brain-targeted drug delivery by manipulating protein corona functions
Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11593-z · Cited by 334 · see citing works
Digiacomo, L., Cardarelli, F., Pozzi, D., Palchetti, S., Digman, M. A., Gratton, E., Capriotti, A. L., Mahmoudi, M., & Caracciolo, G. (2017) · Nanoscale · doi:10.1039/c7nr06437c · Cited by 109 · see citing works
Self-citationHo, Y. T., Kamm, R. D., & Kah, J. C. Y. (2018) · Nanoscale · doi:10.1039/c8nr02393j · Cited by 102 · see citing works
Magnetic nanomaterials for wireless thermal and mechanical neuromodulation
Signorelli, L., Hescham, S. A., Pralle, A., & Gregurec, D. (2022) · iScience · doi:10.1016/j.isci.2022.105401 · Cited by 32 · see citing works
- Authors
- Caracciolo, G., Farokhzad, O. C., & Mahmoudi, M.
- Affiliations
- Sapienza University of Rome (IT)
- Brigham and Women's Hospital (US)
- Corresponding author
- Farokhzad, Omid C.
- Mahmoudi, Morteza
- Venue
- Trends in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 35
- Issue
- 3
- Pages
- 257-264
- ISSN
- 0167-7799 (ISSN-L)
- OpenAlex
- W2523119479
- Cited by
- 426
- References
- 1
- Citations by year
- 2026: 40 · 2025: 35 · 2024: 35 · 2023: 33 · 2022: 38 · 2021: 43 · 2020: 67 · 2019: 55 · 2018: 48 · 2017: 29 · 2016: 2
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Trends in biotechnology (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Physical Sciences › Materials Science › Materials Chemistry › Nanoparticles: synthesis and applications
- Keywords
- protein corona, nanoparticles, nanoparticle-biomolecule interactions, quantitative model, nanoparticle biodistribution, nanoparticle toxicity
- MeSH terms
- Protein Corona, Animals, Humans, Biomedical Research, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
